<i id='2244BC65BB'><strike id='2244BC65BB'><tt id='2244BC65BB'><pre id='2244BC65BB'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
State Dept. review finds Biden bears some blame for Afghanistan failures 
Nearly two 
Duchenne breakthrough therapy leaves behind pioneering families 
2 US Navy sailors arrested for allegedly spying for China 
Activists slam private health insurers over coverage restrictions 
Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast 
The Supreme Court will review a ruling striking down a domestic violence federal gun ban 
Belarusian journalist sentenced to 4 years in prison as crackdown continues 
Guidelines to prevent youth baseball injuries need more muscle 
ADA: All diabetes patients should be screened for liver condition 
Continuity nursing helped my family in our darkest PICU moments 
GOP hopefuls to address prominent, controversial group questioning what's taught in schools 
Hollywood unions extend contract negotiations for actors 
What the cancer research community can learn from the Covid response
Guidelines to prevent youth baseball injuries need more muscle 